MX2009010639A - Nuevo antigeno asociado con la neovasculatura de metastasis tumoral. - Google Patents

Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.

Info

Publication number
MX2009010639A
MX2009010639A MX2009010639A MX2009010639A MX2009010639A MX 2009010639 A MX2009010639 A MX 2009010639A MX 2009010639 A MX2009010639 A MX 2009010639A MX 2009010639 A MX2009010639 A MX 2009010639A MX 2009010639 A MX2009010639 A MX 2009010639A
Authority
MX
Mexico
Prior art keywords
neovasculature
fibrinogen
antigen
tumour metastases
metastases
Prior art date
Application number
MX2009010639A
Other languages
English (en)
Spanish (es)
Inventor
Dario Neri
Giovanni Neri
Jascha Rybak
Christoph Roesli
Alessandra Villa
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of MX2009010639A publication Critical patent/MX2009010639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2009010639A 2007-04-02 2008-03-31 Nuevo antigeno asociado con la neovasculatura de metastasis tumoral. MX2009010639A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90958007P 2007-04-02 2007-04-02
US94856407P 2007-07-09 2007-07-09
PCT/IB2008/000965 WO2008120101A2 (en) 2007-04-02 2008-03-31 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Publications (1)

Publication Number Publication Date
MX2009010639A true MX2009010639A (es) 2009-10-23

Family

ID=39791007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010639A MX2009010639A (es) 2007-04-02 2008-03-31 Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.

Country Status (12)

Country Link
US (5) US8263041B2 (cg-RX-API-DMAC7.html)
EP (2) EP2142567B1 (cg-RX-API-DMAC7.html)
JP (2) JP5221641B2 (cg-RX-API-DMAC7.html)
KR (1) KR101515243B1 (cg-RX-API-DMAC7.html)
CN (2) CN101687923B (cg-RX-API-DMAC7.html)
AU (1) AU2008234615B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809989B8 (cg-RX-API-DMAC7.html)
CA (1) CA2682851C (cg-RX-API-DMAC7.html)
EA (2) EA036322B1 (cg-RX-API-DMAC7.html)
ES (2) ES2609813T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009010639A (cg-RX-API-DMAC7.html)
WO (1) WO2008120101A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817005B2 (ja) 1990-06-29 1998-10-27 スズキ株式会社 エンジン用オーバヒート検出装置
EA036322B1 (ru) 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
BRPI0812765B8 (pt) * 2007-07-25 2022-12-27 Philogen Spa Usos de um anticorpo que se liga à isoforma com domínio-a extra (ed-a) de fibronectina
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
PT2903629T (pt) 2012-10-03 2019-09-10 Philogen Spa Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino
KR20160108322A (ko) 2013-12-12 2016-09-19 유엠씨 우트레크트 홀딩 비.브이. 피브로넥틴-eda에 대해 유도된 면역글로불린-유사 분자
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
RU2018105687A (ru) 2015-07-16 2019-08-16 Филоджен С.П.А. Иммуноконъюгаты на основе il22
EP4617283A2 (en) 2016-10-17 2025-09-17 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN110997718B (zh) 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
US20220305135A1 (en) * 2019-06-03 2022-09-29 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
US11787875B2 (en) 2019-08-15 2023-10-17 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
CN114350518B (zh) * 2022-01-19 2023-01-13 广东乾晖生物科技有限公司 仿生肝微流控细胞培养-药物筛选芯片
EP4493210A1 (en) 2022-03-17 2025-01-22 Universitätsklinikum Jena Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
FI892197A7 (fi) * 1989-05-08 1990-11-09 Locus Oy Foerfarande foer detektering av tumoerer.
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (fr) * 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
WO2001076630A1 (en) 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
CA2421783A1 (en) 2000-09-07 2002-03-14 Schering Aktiengesellschaft Receptor in the edb fibronectin domain
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
RU2352582C2 (ru) * 2002-01-03 2009-04-20 Шеринг Акциенгезельшафт Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2523452A1 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
EP1660519B1 (en) 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
US20060024757A1 (en) 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
BRPI0517967B8 (pt) 2004-11-09 2021-05-25 Philogen Spa anticorpo isolado que liga-se a tenascina-c humana
MX2007013875A (es) 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
BRPI0709787A2 (pt) 2006-05-08 2011-03-29 Philogen Spa citocinas com anticorpos alvejados para terapia
EA036322B1 (ru) 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
BRPI0812765B8 (pt) 2007-07-25 2022-12-27 Philogen Spa Usos de um anticorpo que se liga à isoforma com domínio-a extra (ed-a) de fibronectina
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
ES2549362T3 (es) * 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
BR112013007160A2 (pt) * 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
ES2706428T3 (es) * 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
AU2014257906A1 (en) * 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
KR101515243B1 (ko) 2015-04-24
US8263041B2 (en) 2012-09-11
EA200970909A1 (ru) 2010-10-29
CN101687923A (zh) 2010-03-31
US8481684B2 (en) 2013-07-09
US20100247541A1 (en) 2010-09-30
WO2008120101A3 (en) 2008-12-11
EA201301224A1 (ru) 2014-07-30
US9181347B2 (en) 2015-11-10
AU2008234615A1 (en) 2008-10-09
CN103275220A (zh) 2013-09-04
EP2653478A1 (en) 2013-10-23
AU2008234615B2 (en) 2013-10-10
CN101687923B (zh) 2013-06-19
US20130280759A1 (en) 2013-10-24
HK1184794A1 (zh) 2014-01-30
ES2402171T3 (es) 2013-04-29
JP5221641B2 (ja) 2013-06-26
JP2010523541A (ja) 2010-07-15
BRPI0809989B8 (pt) 2021-05-25
JP5840631B2 (ja) 2016-01-06
US20130040361A1 (en) 2013-02-14
US9896503B2 (en) 2018-02-20
US20130266511A1 (en) 2013-10-10
EP2653478B1 (en) 2016-10-05
EA036322B1 (ru) 2020-10-26
HK1140217A1 (en) 2010-10-08
BRPI0809989A2 (pt) 2015-09-29
CA2682851C (en) 2017-01-17
CN103275220B (zh) 2016-01-20
EA018985B1 (ru) 2013-12-30
US20160083461A1 (en) 2016-03-24
CA2682851A1 (en) 2008-10-09
EP2142567B1 (en) 2013-01-16
BRPI0809989B1 (pt) 2019-10-08
EP2142567A2 (en) 2010-01-13
JP2013121353A (ja) 2013-06-20
KR20100016094A (ko) 2010-02-12
WO2008120101A2 (en) 2008-10-09
ES2609813T3 (es) 2017-04-24

Similar Documents

Publication Publication Date Title
MX2009010639A (es) Nuevo antigeno asociado con la neovasculatura de metastasis tumoral.
WO2009013619A3 (en) The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
PH12013502230A1 (en) Multispecific antibodies
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MX2010002783A (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa.
EP4516811A3 (en) Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
EA201200999A1 (ru) Способы лечения рака молочной железы
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2011013351A (es) Materiales de soporte inorgánicos que contienen compuestos de 3 anillos heterocíclicos.
MX2016008418A (es) Metodos y reactivos para el radiomarcaje.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration